Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108568 | 0.83 | CYP1A2 (0.33) | CA2CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL10102749 | 0.74 | KMT2A (0.40) | MAPTCA2CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL9291606 | 0.65 | CYP1A2 (0.36) | CA2CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL9291884 | 0.65 | CYP1A2 (0.33) | CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL12824764 | 0.64 | CYP1A2 (0.35) | CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL11867402 | 0.62 | MAPT (0.43) | MAPTCA2ALDH1A1 | |
| SCHEMBL10102782 | 0.61 | KMT2A (0.39) | MAPTCYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL11982518 | 0.60 | KMT2A (0.50) | MAPTALDH1A1 | |
| SCHEMBL7508757 | 0.58 | PDE4A (0.39) | MAPTCYP1A2ALDH1A1 | |
| SCHEMBL19270496 | 0.58 | CA2 (0.68) | CA2CYP1A2CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | MAPT 3315/4885CA2 2046/4885CYP1A2 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.